Exposure-response Analysis of Pertuzumab in HER2-positive Metastatic Breast Cancer: Absence of Effect on QTc Prolongation and Other ECG Parameters Publication Exposure-response Analysis of Pertuzumab in HER2-positive Metastatic Breast Cancer: Absence of Effect on QTc Prolongation and Other ECG Parameters The phase III trial of pertuzumab plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus…Certara2013 年 9 月 3 日
Toxicokinetics/Toxicodynamics of γ-hydroxybutyrate-ethanol Intoxication: Evaluation of Potential Treatment Strategies Publication Toxicokinetics/Toxicodynamics of γ-hydroxybutyrate-ethanol Intoxication: Evaluation of Potential Treatment Strategies γ-Hydroxybutyrate (GHB), a common drug of abuse, is often coingested with ethanol. Increasing renal clearance…Certara2013 年 9 月 1 日
Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part I—Digoxin Pharmacokinetic Incorporating P-glycoprotein-mediated Efflux Publication Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part I—Digoxin Pharmacokinetic Incorporating P-glycoprotein-mediated Efflux A prerequisite for the prediction of the magnitude of P-glycoprotein (P-gp)-mediated drug-drug interactions between digoxin…Certara2013 年 9 月 1 日
Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part II—Prediction of P-glycoprotein Mediated Drug-drug Interactions with Digoxin Publication Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part II—Prediction of P-glycoprotein Mediated Drug-drug Interactions with Digoxin Digoxin is the recommended substrate for assessment of P-glycoprotein (P-gp)-mediated drug-drug interactions (DDIs) in vivo.…Certara2013 年 9 月 1 日
Using Historical Control Information for the Design and Analysis of Clinical Trials with Overdispersed Count Data Publication Using Historical Control Information for the Design and Analysis of Clinical Trials with Overdispersed Count Data Results from clinical trials are never interpreted in isolation. Previous studies in a similar setting…Certara2013 年 9 月 1 日
Siponimod for Patients with Relapsing-remitting Multiple Sclerosis (BOLD): An Adaptive, Dose-ranging, Randomized, Phase 2 Study Publication Siponimod for Patients with Relapsing-remitting Multiple Sclerosis (BOLD): An Adaptive, Dose-ranging, Randomized, Phase 2 Study Siponimod is an oral selective modulator of sphingosine 1-phosphate receptor types 1 and type 5,…Certara2013 年 9 月 1 日
Accounting for Transporters in Renal Clearance: Towards a Mechanistic Kidney Model (Mech KiM) Publication Accounting for Transporters in Renal Clearance: Towards a Mechanistic Kidney Model (Mech KiM) The impact of transporters in modulating the disposition of drugs in the liver and their…Certara2013 年 8 月 20 日
Temporal Profile of Lymphocyte Counts and Relationship with Infections with Fingolimod Therapy Publication Temporal Profile of Lymphocyte Counts and Relationship with Infections with Fingolimod Therapy Reduction in peripheral blood lymphocytes is an expected pharmacodynamic outcome of fingolimod therapy. The objective…Certara2013 年 8 月 15 日
Basic Concepts in Physiologically-based Pharmacokinetic Modeling in Drug Discovery and Development Publication Basic Concepts in Physiologically-based Pharmacokinetic Modeling in Drug Discovery and Development The aim of this tutorial is to introduce the concept of physiologically based pharmacokinetic (PBPK)…Certara2013 年 8 月 1 日
Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-patient Study Designs in Psoriasis Publication Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-patient Study Designs in Psoriasis Clinical trial simulation (CTS) and model-based meta-analysis (MBMA) can increase our understanding of small, first-in-patient…Certara2013 年 7 月 24 日